Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ -- Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

HER2+ patients are commonly identified as high risk, yet MammaPrint was able to identify a low risk subgroup of HER2+ patients, who subsequently experienced a 10 year disease-free survival of close to 90 percent even in the absence of (neo)adjuvant trastuzumab (Herceptin(R)) and chemotherapy. Additionally, in a subgroup of highly endocrine responsive HER2/NEU positive patients, MammaPrint(R) low risk patients had no relapse.

The results were presented by Dr. Michael Knauer during the 2008 San Antonio Breast Cancer Symposium (SABCS). In the study population of 169 HER2+ patients MammaPrint(R) classified 16 percent of patients as having a good prognosis signature with a 10-year distant disease-free survival (DDFS) of 89 percent, compared to 84 percent of patients classified as having a poor prognosis signature with a DDFS of 64 percent.

MammaPrint(R)'s robustness is underscored by the 70 gene panel unique to the test and a resulting gene profile that covers all molecular pathways associated with breast cancer. HER2/NEU-overexpression is observed in 15-20 percent of invasive breast cancers and is widely considered to be a negative prognostic factor. As a result, current treatment guidelines classify all HER2-positive breast cancer patients at high risk of relapse, and recommend trastuzumab and chemotherapy.

MammaPrint(R) accurately identified a subgroup of patients with a good clinical outcome in HER2+ early breast cancer. These patients will be further studied in the ongoing MINDACT-trial (Microarra
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... Pumps, today announced the closing of its previously announced underwritten ... price to the public of $11.50 per share, which includes ... to purchase up to an additional 787,500 shares. All of ... BofA Merrill Lynch and Piper Jaffray ...
(Date:3/4/2015)... March 4, 2015  Nevro Corp. (NYSE: ... and commercialized an innovative, evidence-based neuromodulation platform for the ... release financial results for the fourth quarter  and full ... 18, 2015. Company management will host a conference call ... Time) on Wednesday, March 18, 2015. ...
(Date:3/4/2015)... 4, 2015  Mail-service and specialty pharmacies will ... and government health plans $11.8 billion over the ... Pharmaceutical Care Management Association (PCMA). "Home ... of the easiest ways to reduce health costs," ... . "Policymakers should resist efforts to restrict these ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Illinois Employers, Consumers and Public Programs by $11.8 Billion 2
(Date:3/5/2015)... California (PRWEB) March 05, 2015 Developers ... plugins have announced a new effect preset entitled ... allows users to take advantage of combining halftone and ... competition,” said Christina Austin, CEO of Pixel Film Studios. ... users will love.” , With ProHalftone users can now ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Affirmed Housing ... for Cielo Carmel on March 4 at 10AM. ... speakers: Sherri Lightner, Council president, City of San ... Charmaine Atherton, Senior Vice President, Southern California Community Development, ... & CEO, San Diego Housing Commission. , ...
(Date:3/5/2015)... 2015 In recognition of its ongoing ... Soho Flordis International (SFI) has been honored by the ... global natural medicine company committed to identifying and developing ... safety, and effectiveness. For these efforts the non-profit ABC ... Investment in Phytomedicinal Research Award. , Phytomedicinal research ...
(Date:3/5/2015)... Atlanta, GA (PRWEB) March 05, 2015 ... Kung Fu for Health and Wellness at Atlanta Shaolin ... 2015 on 4350 Peachtree Industrial BLVD, Suite 500A, city ... SCF (Shaolin Chan Foundation), which is a non-profit organization ... culture, arts, philosophy and medicine. , The seminar ...
(Date:3/4/2015)... 2015 Understanding China’s New Medical Device ... – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs , There ... for medical devices in China. , These new ... research and development, approval, manufacturing, distribution, and post-market surveillance. ... in development as well as those that are already ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released ProHalftone Exclusively for Final Cut Pro X Editors 2Health News:SD City Council President Sherri Lightner and Affirmed Housing Break Ground on Affordable Homes in Carmel Valley 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 3Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3
... / Heidelberg, 9 January 2012 -- Confronted with a high ... treat aggressively with medications. According to new research, however, delaying ... be harmful. The delay allows doctors and their patients to ... and exercise. According to Neda Laiteerapong and colleagues from the ...
... Center researchers identified a new culprit that leads to ... into plaque and narrows arteries. The research, published online ... explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, ... macrophages that accumulate in plaques secrete a molecule called ...
... Reporter , FRIDAY, Jan. 6 (HealthDay News) -- Annual ... new study that is unlikely to quell the controversy ... "Organized prostate cancer screening when done in addition to ... result in any apparent benefit, but does result in ...
... Jan. 9 (HealthDay News) -- Most parents who have genetic ... children, a new study finds. Researchers interviewed 253 parents ... cancer-related genes (BRCA1 and BRCA2) that can be inherited. All ... time of the genetic test. Twenty-nine percent of the ...
... Researchers at the Translational Genomics Research Institute (TGen) have ... lead to lung cancer in never-smokers a first ... the starting point. We certainly have a lot of ... be very interested in confirming and looking at in ...
... found that when parents get tested for breast cancer genes, ... with those who are very young. Published early online in ... Society, the study also revealed that most parents think that ... test results. For parents, one of the primary motivations ...
Cached Medicine News:Health News:Blood pressure control: Now or later? 2Health News:Researchers discover new culprit in atherosclerosis 2Health News: PSA Test for Prostate Cancer Doesn't Save Lives: Study 2Health News: PSA Test for Prostate Cancer Doesn't Save Lives: Study 3Health News:Most Parents Tell Kids About Test Results for Breast Cancer Genes 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2Health News:Most parents who get tested for breast cancer genes share results with their children 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: